PIK3CA and esophageal squamous cell carcinoma: We have reported that the clinical PI3Kα-selective inhibitor CYH33 displayed potent activity against ESCC in vitro and in vivo.18,19 Though PI3K is frequently over-activated in ESCC,20 ESCC is highly heterogeneous in terms of molecular signatures.